KERYX BIOPHARMACEUTICALS INC
KERYX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for KERYX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Sep 30, 2018.
Tracking 1 pipeline candidate · 2 clinical trials · 1 FDA decision for KERYX BIOPHARMACEUTICALS INC.
Run KERYX BIOPHARMACEUTICALS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available KERYX BIOPHARMACEUTICALS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
8.6 months
OCF -$23M · Net income -$17M
Lead: Approved
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is KERYX BIOPHARMACEUTICALS INC's lead drug candidate?
KERYX BIOPHARMACEUTICALS INC's most advanced tracked candidate is auryxia (Approved) for Treatment of iron deficiency anemia in adults with CKD, not on dialysis.
Who is the CEO of KERYX BIOPHARMACEUTICALS INC?
Jodie P. Morrison Interim is the chief executive officer of KERYX BIOPHARMACEUTICALS INC (KERYX).
What therapeutic areas does KERYX BIOPHARMACEUTICALS INC focus on?
KERYX BIOPHARMACEUTICALS INC develops therapies across Hematology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.